scholarly journals Multifocal Metachronous Giant Cell Tumor: Case Report and Review of the Literature

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
B. Ghostine ◽  
A. Sebaaly ◽  
I. Ghanem
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Recurrence Rate ◽  
Correct Diagnosis ◽  
Cell Tumor ◽  
High Recurrence Rate ◽  
Giant Cell Tumors ◽  
Radiographic Findings ◽  
Female Predominance ◽  
Histological Characteristics

Introduction. Giant cell tumors (GCTs) of bone are known for their local aggressiveness and high recurrence rate. There are rare cases of multicentric GCT and most are synchronous. We herein review metachronous multicentric GCT reported in the literature.Material and Methods. A MEDLINE, Cochrane, and Google Scholar search was done to collect all cases of multicentric metachronous GCT specifying the clinical, radiological, and histological characteristics of each location and its treatment.Results. A total of 37 multifocal giant cell tumors were found in the literature. 68% of cases of multicentric giant cell tumors occur in less than 4 years following treatment of the first lesion. Thirty-seven cases of multifocal metachronous GCT were identified in the literature until 2012. Patients with multicentric GCT tend to be younger averaging 23. There is a slight female predominance in metachronous GCT. The most common site of the primary GCT is around the knee followed by wrist and hand and feet. Recurrence rate of multicentric GCT is 28.5%.Conclusion. Multicentric giant cell tumor is rare. The correct diagnosis relies on correlation of clinical and radiographic findings with confirmation of the diagnosis by histopathologic examination.

Giant Cell Tumor of the Talar Neck

2007 ◽  
Vol 97 (3) ◽  
pp. 225-228 ◽  
Author(s):  
Hakan Selek ◽  
Hamza Özer ◽  
Sacit Turanli ◽  
Özlem Erdem
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Clinical Signs ◽  
Cell Tumor ◽  
Giant Cell Tumors ◽  
Radiographic Appearance ◽  
Aneurysmal Bone Cysts ◽  
Tumors Of Bone ◽  
Brown Tumors ◽  
Small Bones

We describe a patient with a giant cell tumor in the talar head and neck of the left foot who was diagnosed as having osteochondritis dissecans and treated with arthroscopic drilling in this same location 3 years earlier. Giant cell tumors can be confused with several conditions, including giant cell reparative granulomas, brown tumors, and aneurysmal bone cysts. Giant cell tumors of bone typically occur in the epiphysis of long bones, including the distal femur and proximal tibia. They are uncommonly found in the small bones of the foot or ankle, and talar involvement is rare. Despite this rarity, the radiographic appearance and clinical signs of talar lesions should be considered in the differential diagnosis of nontraumatic conditions in the foot. (J Am Podiatr Med Assoc 97(3): 225–228, 2007)

Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel CSF1-CD96 Fusion Transcript

2021 ◽  
pp. 106689692110498
Author(s):  
Haider Mejbel ◽  
Gene P. Siegal ◽  
Shi Wei
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Gene Rearrangement ◽  
Fusion Transcript ◽  
Cell Tumor ◽  
Molecular Profile ◽  
Small Subset ◽  
Fusion Partner ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors typically arise in the synovium of joints, bursae, or tendon sheaths. They may occur in an intra- or extra-articular location and can be divided into localized and diffuse types. The neoplastic nature of the lesion has been supported by a recurrent CSF1 gene rearrangement in a small subset of lesional cells, of which the most common fusion partner is COL6A3. Herein, we report a case of intramuscular localized tenosynovial giant cell tumor harboring a novel CSF1-CD96 fusion transcript, thus expanding the molecular profile of this tumor.

scholarly journals Correlation between Campanacci’s radiological classification of giant cell tumor of bone and expression of Cyclin D1 and PCNA

2017 ◽  
Vol 7 (1) ◽  
pp. 47
Author(s):  
Eréndira G. Estrada-Villaseñor ◽  
Hidalgo Bravo Alberto ◽  
C. Bandala ◽  
P. De la Garza-Montano ◽  
Reyes Medina Naxieli ◽  
...  
Keyword(s):  
Cyclin D1 ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Descriptive Study ◽  
Cell Tumor ◽  
Giant Cell Tumors ◽  
Radiological Classification ◽  
Tumors Of Bone ◽  
Made In

Giant cell tumor of bone is considered by his behavior a benign but aggressive neoplasm. The objective of our study was to determine if there is a correlation between the Campanacci’s radiological classification of giant cell tumors of bone and the expression by immunohistochemistry of Cyclin D1 and proliferation cell nuclear antibody (PCNA). A retrospective and descriptive study was made. In total, there were 27 cases. All cases showed Cyclin D1 and PCNA positivity. Rho Spearman for Campanacci and Cyclin D1 expression was 0.06 and for Campanacci and PCNA was 0.418. We conclude that there is a positive correlation between PCNA expression in giant cell tumors of Bone and the Campanacci’s radiological classification II and III, butCyclin D1 expression was no related with radiologic features.

Giant Cell Tumor of the Ethmoid Sinus: An Unusual Cause of Proptosis in a Child

1982 ◽  
Vol 90 (4) ◽  
pp. 513-515 ◽  
Author(s):  
Steven D. Handler ◽  
Peter J. Savino ◽  
Robert G. Peyster ◽  
Norman J. Schatz
Keyword(s):  
Head And Neck ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Ethmoid Sinus ◽  
Cell Tumor ◽  
Giant Cell Tumors

Giant cell tumors (osteoclastoma) occur infrequently in the head and neck and are extremely rare in children. The occurrence of such a lesion in the ethmoid sinus of a 14-year-old girl is presented and discussed.

Recurrence Potential of Diffuse-Type Giant Cell Tumor in the Foot: Radiologic and Pathologic Features

2005 ◽  
Vol 26 (6) ◽  
pp. 474-478 ◽  
Author(s):  
Tominaga Shimizu ◽  
Takeshi Uehara ◽  
Tsutomu Akahane ◽  
Kenichi Isobe ◽  
Hideki Arai
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Tumor Resection ◽  
Cell Tumor ◽  
Cell Contact ◽  
Diffuse Type ◽  
Mri Findings ◽  
Giant Cell Tumors ◽  
Pathologic Features ◽  
Type Giant

Background: Aggressive musculoskeletal tumors in the foot, such as diffuse-type giant cell tumors or extra-abdominal desmoid tumors, are difficult to treat because the foot does not have enough soft tissue to allow wide tumor resection. We reviewed the clinical behavior of diffuse-type giant cell tumor in the foot and evaluated the recurrence potential of these tumors from radiologic and pathologic perspectives. Methods: Six patients with a mean age of 37.6 years were included in this study. Radiologic studies, including sonography, computed tomography (CT), magnetic resonance imaging (MRI), and bone and gallium citrate scintigraphy, were obtained followed by surgical treatment and histologic evaluation of the tumor. Results: Recurrence occurred in three patients. Although CT and MRI findings were similar in the recurrent and nonrecurrent tumors, marked differences were found between the two by scintigraphy; positive radiotracer uptake to the affected foot with gallium citrate scintigraphy was noted only in recurrent tumors, although positive accumulation was seen in all patients with bone scintigraphy. Histologically, the necrotic area and mitotic activity were more apparent in recurrent than in the nonrecurrent tumors, and tumor cell dyscohesion was noted in the former, (the intercellular space was increased). Conclusions: Repeated recurrence with tumor invasion into tarsal bone resulted in breakage of the tarsal arch that supports the body's weight. Amputation would be necessary for patients in whom the disease had progressed to obtain local cure and relief of pain. In the present study, we found two features of the recurrence potential of diffuse-type giant cell tumors: sparse cell to cell contact on pathologic examination and positive accumulation in the tumor on gallium citrate scintigraphy. We concluded that giant cell tumors with these two features have a strong potential for local recurrence, and thus require intensive followup.

Giant Cell Tumor of the Larynx

1998 ◽  
Vol 107 (8) ◽  
pp. 729-732 ◽  
Author(s):  
Kenneth O. Devaney ◽  
Alfio Ferlito ◽  
Alessandra Rinaldo
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Malignant Fibrous Histiocytoma ◽  
Fibrous Histiocytoma ◽  
Sarcomatoid Carcinoma ◽  
Cell Tumor ◽  
Long Bone ◽  
Giant Cell Tumors ◽  
Tentative Diagnosis ◽  
True Neoplasm

Among the more uncommon tumors that may sometimes be encountered in the laryngeal region is the recently described giant cell tumor of the larynx. This lesion is a true neoplasm, presumably of the fibrohistiocytic series. Histologically, it closely resembles the more familiar true giant cell tumor of long bone. The laryngeal giant cell tumors appear, to date, to be nonmetastasizing lesions; it is possible that they may recur locally if incompletely excised (although this remains to be demonstrated). In view of the rarity of these tumors, a tentative diagnosis of such a neoplasm should always prompt consideration of other (more frequently encountered) differential diagnostic possibilities, including cytologically malignant giant cell-rich tumors such as malignant fibrous histiocytoma and sarcomatoid carcinoma.

scholarly journals Giant cell tumor of tendon sheath: a case series

2018 ◽  
Vol 5 (6) ◽  
pp. 2372
Author(s):  
Ramesh Kumar Korumilli ◽  
Jakkula Srikanth ◽  
Sri Harsha Muvva ◽  
B. M. Yashwanth Reddy
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Case Series ◽  
Surgical Excision ◽  
Tendon Sheath ◽  
Degenerative Joint Disease ◽  
Cell Tumor ◽  
Joint Disease ◽  
High Recurrence Rate ◽  
Malignant Soft Tissue Tumor

Giant cell tumor of tendon sheath is a relatively rare non-malignant soft tissue tumor arising from the synovial cells and is associated with high recurrence rate. Many factors are considered for high recurrence including proximity to distal interphalangeal joints, presence of degenerative joint disease, pressure erosions in the radiograph and increased mitotic activity. But the most common cause for recurrence is incomplete surgical excision. However, it is the second most common tumor in hands after ganglion cysts. Here we present a case series comprising of 3 cases for whom marginal excision was done and they were kept on regular follow up without any recurrence.

scholarly journals Dorsal Spine Giant Cell Tumor with paraplegia: A Case Report

2015 ◽  
Vol 31 (1) ◽  
pp. 45-49
Author(s):  
Md Atikur Rahman ◽  
Mohammad Hossain ◽  
ATM Mosharef Hossain
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Osteolytic Lesion ◽  
Cell Tumor ◽  
Posterior Arch ◽  
Thoracic Region ◽  
Giant Cell Tumors ◽  
Surgical Biopsy ◽  
Dorsal Vertebra ◽  
Transpedicular Fixation

Patients of Giant cell tumors (GCT) of the spine is rarely seen . We reported a case of GCT of the eleventh dorsal vertebra presented by severe backache with paraplegia in a 30 year old woman. Imaging showed an osteolytic lesion invading the vertebral body, the posterior arch and compression of the spinal cord. Neurological decompression was performed but pain recurred after 2 months. The MRI of spine revealed recurrence of tumor and again surgical decompressions was done along with long segment transpedicular fixation and patient was significantly improved. A surgical biopsy was obtained at the same time to confirm the diagnosis. Giant cell tumor is not so common in thoracic region. We believe that the gross removal of tumor provide good outcome for the patient. Bangladesh Journal of Neuroscience 2015; Vol. 31 (1): 45-49

scholarly journals Managing Sacral Giant Cell Tumor with Surgery and Various Adjuvant Therapies

2020 ◽  
Author(s):  
Yushen Zhang ◽  
Jun Fu ◽  
Yingsen Xue ◽  
Zheng Guo ◽  
Zhen Wang ◽  
...  
Keyword(s):  
Blood Loss ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Recurrence Rate ◽  
Operation Time ◽  
Arterial Embolization ◽  
Cell Tumor ◽  
Adjuvant Therapies ◽  
Group A ◽  
Group B

Abstract Background and purpose: There is no consensus regarding the appropriate treatment of sacral giant cell tumor (SGCT). This study is to compare oncological and neurological outcomes of SGCT managed by surgery and various adjunctive therapies.Methods: A total of 31 patients with SGCT were retrospectively studied. They were divided into two Groups. A: 13 patients underwent surgery plus SAE and radiotherapy; Group B: 18 patients underwent surgery plus one arterial embolization and denosumab. The postoperative functional outcomes, recurrence, mortality, and complications were compared.Results: The mean operation time (231±49min) and blood loss (3167±856mL) of group B were significantly less than those of group A (283±41min, 5054±689mL) (p<0.05). The average follow-up was 68.5 months. The neurologic function scores showed no significant difference. The recurrence rate of group B (11.2%) was much lower than that of group A (30.7%, p=0.17). The cumulative survival rate of group B was higher than that of group A (p=0.133).Conclusions: In comparison to other adjuvant therapies, one arterial embolization plus denosumab can reduce the intra-operative blood loss, shorten the operation time, and decrease the recurrence rate in patients with SGCT.

Sign in / Sign up

Export Citation Format

Share Document